Skip to main content

Cambridge biotech opts for Nasdaq listing over LSE’s AIM

Life sciences research tool supplier Abcam said it will seek to delist from the AIM on London’s stock exchange following a “positive shareholder response”.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.